Indicated to address treatment-resistant schizophrenia to relieve severe psychiatric symptoms and support mental stabilization.
Mechanism of Action
Antagonizes dopamine D2 and serotonin 5-HT2A receptors with high affinity, normalizing hyperactive central pathways without producing extrapyramidal dominance.
Route of Administration
Oral
Onset Time
1–2 weeks
Duration
24 hours
Contraindications
History of drug-induced agranulocytosis, Severe bone marrow disorders, Uncontrolled epilepsy
Severe Adverse Events
Agranulocytosis — requires immediate medical attention, Myocarditis — requires immediate medical attention, Seizures — requires immediate medical attention
Common Side Effects
Somnolence, Dizziness, Sialorrhea
Uncommon Side Effects
Tachycardia, Weight gain, Constipation
Drug Interactions
Alcohol, Benzodiazepines, Ciprofloxacin
Pregnancy Safety Warnings
TGA Category B: Safety established in animal studies. Breastfeeding: Contraindicated.
Information related to Clozaril is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
